Supporting biotechnology companies and academic research teams with in-vivo pharmacology, preclinical PK/PD, and translational biomarker strategies to advance scientific research and drug development.
Specialized services for biotech programs and academic laboratories. Select an audience to explore specific capabilities.
Preclinical pharmacology, translational biomarkers, and scientific program support for drug discovery and development teams.
WHERE I CONTRIBUTE
Across the drug development pathway
The teal region identifies my core preclinical focus and related IND-enabling pharmacology support.
01Target Identification
02In-Vitro Pharmacology
03In-Vivo Pharmacology
04Biomarkers & Translation
05IND-Enabling Studies
06Clinical Development
Focus: in-vivo pharmacology and translational biomarker strategy, with selected contributions to IND-enabling activities — not clinical development services.
Experimental research support and academic-to-industry translation for laboratories seeking rigorous, actionable scientific guidance.
ABOUT ME
From academic neuroscience to preclinical drug development
Géraldine Gontier, PhD
I am a neuroscientist and independent scientific consultant with over 17 years of research experience spanning neuroscience, aging biology, and biotechnology drug development.
My career began in academic research, investigating the molecular mechanisms of aging and neurodegeneration. I subsequently transitioned into biotechnology, focusing on in-vivo pharmacology, preclinical PK/PD, and translational biomarker development across neurological and metabolic diseases.
Today, I support biotech companies and academic laboratories with scientific expertise to advance research, strengthen preclinical development strategies, and guide data-driven decisions.
01
PhD · Pierre and Marie Curie University
Physiology, neuroscience, and aging biology.
02
Postdoctoral Research · UCSF
Brain aging, epigenetics, and regenerative mechanisms.
03
Scientist · Unity Biotechnology
Preclinical neurodegeneration research and therapeutic programs.
04
Principal Scientist · Verge Genomics
In-vivo pharmacology, PK/PD, biomarkers, and preclinical program leadership.
05
Independent Scientific Consultant · Present
Preclinical pharmacology and translational support for biotech and academia.
SCIENTIFIC CONTRIBUTIONS
Evidence-driven scientific experience
Selected examples from preclinical drug development, biomarker translation, and neuroscience research.
01 · DRUG DEVELOPMENT
Preclinical Drug Development
Contributions to preclinical small-molecule programs across neurological and metabolic diseases, integrating in-vivo pharmacology, PK/PD, efficacy, and biomarker evidence to inform program decisions.
Public-facing description; confidential results and internal milestones are not disclosed.
02 · BIOMARKER SCIENCE
Translational Biomarker Development
Development of pharmacodynamic biomarker strategies, including GPNMB as a translational readout of PIKfyve inhibition, connecting preclinical models and clinical biomarker evaluation.
View publication ⌄
Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB): A Translational Pharmacodynamic Biomarker for PIKfyve Inhibition with VRG50635
Gontier G.**, Kim G.**, Wang C., Zhu K., Gau R., Zhang N., Naphade S., Stewart A., Schmidt M.J., Galemmo R., Shook B., Tarachandani A., Choi I., Raines S., Scannevin R.H., Grievink H.W., Smits L.M.G., Kremer P.H.C., Cadavid D. (2026). Clinical and Translational Science.